Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 16/20 | 0.43 |
| ▸ | CNR1 | P21554 | 4/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 5/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3990908 | 0.86 | CNR2 (0.49) | CNR2CNR1CYP3A4CYP2C9CYP2C19 | |
| Hydrochloric Acid SCHEMBL3990784 | 0.86 | CNR2 (0.48) | CNR2CNR1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL3993460 | 0.82 | CNR2 (0.42) | CNR2CNR1CYP3A4CYP2C9CYP2C19 | |
| Hydrochloric Acid SCHEMBL3996591 | 0.81 | HTR4 (0.35) | CNR2 | |
| Hydrochloric Acid SCHEMBL3996161 | 0.73 | EGFR (0.46) | CNR2CNR1CYP2C9CYP2C19CYP1A2 | |
| Hydrochloric Acid SCHEMBL3988864 | 0.70 | CNR2 (0.49) | CNR2CNR1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL3415849 | 0.70 | CNR2 (0.73) | CNR2CYP3A4CYP2C9CYP2C19CYP1A2 | |
| SCHEMBL14996833 | 0.69 | MAPT (0.53) | CNR2MAPTSIRT5 | |
| SCHEMBL5046083 | 0.69 | CNR2 (0.73) | CNR2CYP3A4CYP2C9CYP2C19CYP1A2 | |
| SCHEMBL3993442 | 0.68 | CNR2 (0.65) | CNR2CNR1CYP3A4CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7589206-B2 | Pyrrolopyridine derivatives | GLAXO GROUP LIMITED (GB) | 2009-09-15 | — | — | US | disclosed |
| EP-1753764-B1 | PYRROLOPYRIDINE DERIVATIVES | GLAXO GROUP LTD (GB) | 2008-10-29 | — | — | EP | disclosed |
| US-20070219229-A1 | Pyrrolopyridine Derivatives | GLAXO GROUP LIMITED (GB) | 2007-09-20 | — | — | US | disclosed |
| EP-1753764-A1 | PYRROLOPYRIDINE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2007-02-21 | — | — | EP | disclosed |
| WO-2005121140-A1 | PYRROLOPYRIDINE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2005-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219229-A1 | Pyrrolopyridine Derivatives | CNR2, CNR1, TRPV1 | CNR2 1/4885CNR1 2/4885CYP3A4 1521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.